Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5644131 | 0.85 | IDO1 (0.42) | IDO1RXRARXRBRXRGSLC6A2 | |
| SCHEMBL4715833 | 0.82 | IDO1 (0.51) | IDO1RXRARXRBRXRGSLC6A2 | |
| SCHEMBL5929043 | 0.81 | RXRA (0.51) | IDO1RXRARXRBRXRGAR | |
| SCHEMBL24146520 | 0.80 | RXRA (0.50) | RXRARXRBRXRGAR | |
| SCHEMBL25826312 | 0.80 | RXRA (0.50) | IDO1RXRARXRBRXRGAR | |
| SCHEMBL549178 | 0.80 | RXRA (0.50) | IDO1RXRARXRBRXRGSLC6A4 | |
| SCHEMBL29507276 | 0.80 | RXRA (0.50) | IDO1RXRARXRBRXRGSLC6A4 | |
| SCHEMBL13637429 | 0.80 | RXRA (0.50) | IDO1RXRARXRBRXRGAR | |
| SCHEMBL195493 | 0.80 | RXRA (0.50) | IDO1RXRARXRBRXRGSLC6A4 | |
| SCHEMBL1538597 | 0.78 | IDO1 (0.63) | IDO1SLC6A2SLC6A4P2RX7HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376463-A1 | PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2025-12-11 | — | — | US | disclosed |
| US-12441706-B2 | Protein degradation agent compound preparation method and application | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2025-10-14 | — | — | US | disclosed |
| CN-113087704-B | Preparation method and application of protein degradation agent compound | 上海济煜医药科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20230111119-A1 | PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2023-04-13 | — | — | US | disclosed |
| EP-4083020-A1 | PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-11-02 | — | — | EP | disclosed |
| CN-112390852-B | Compound as protein degradation agent and preparation method and application thereof | 上海济煜医药科技有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-114829342-A | Preparation method and application of protein degradation agent compound | 上海济煜医药科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-113087704-A | Preparation method and application of protein degradation agent compound | 上海济煜医药科技有限公司 | 2021-07-09 | — | — | CN | disclosed |
| WO-2021129653-A1 | PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION | 上海济煜医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
| CN-112390852-A | Compound as protein degradation agent and preparation method and application thereof | 上海济煜医药科技有限公司 | 2021-02-23 | — | — | CN | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| US-6528657-B2 | For use in electroluminescence light emission element and can emit lights of various colors when an energy such as electric energy or electromagnetic energy is applied thereto | TAIHO INDUSTRIES CO., LTD. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20030023099-A1 | Novel fluorescent carbazole derivative | HIROSE ENGINEERING CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376463-A1 | PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION | AR, PSMA8, PSMA6 | IDO1 3513/4885RXRA 1491/4885RXRB 1676/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | IDO1 54/4885RXRA 2116/4885RXRB 2162/4885 |
| US-20080058383-A1 | Androgen Receptor Modulators | NR5A1, ESRRA, AR | IDO1 3667/4885RXRA 154/4885RXRB 136/4885 |
| US-12441706-B2 | Protein degradation agent compound preparation method and application | AR, PSMA8, PSMA6 | IDO1 3513/4885RXRA 1491/4885RXRB 1676/4885 |
| US-20230111119-A1 | PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION | AR, PSMA8, PSMA6 | IDO1 3513/4885RXRA 1491/4885RXRB 1676/4885 |
| US-20030023099-A1 | Novel fluorescent carbazole derivative | CBR3, AANAT, SIRT3 | IDO1 289/4885RXRA 4472/4885RXRB 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.